MacroGenics’ mission is to discover, develop and deliver to patients novel biologics for the treatment of cancer, autoimmune disorders and infectious diseases. Learn More
MacroGenics' Corporate Fact Sheet
Product Pipeline Highlights
View full chart| Program (Target) | Indication | Lead Opt. | Pre- Clin. |
Ph 1 |
Ph 2 |
Ph 3 |
|---|---|---|---|---|---|---|
| ONCOLOGY | ||||||
| MGAH22 (Anti-HER2)(HER2) | Metastatic Breast | * | * | * | * | * |
| Solid Tumors | * | * | * | * | * | |
| MGA271 (Anti-B7-H3)MGA271 (Anti-B7-H3)(B7-H3) | Solid Tumors | * | * | * | * | * |
| MGD006MGD006 | Hematologic | * | * | * | * | * |
| MGD007MGD007 | Gastrointestinal | * | * | * | * | * |
| OtherOther | Solid Tumors | * | * | * | * | * |
| OtherOther | Various | * | * | * | * | * |
| OtherOther(>75 Targ.) | Solid & Liq. Tumors | * | * | * | * | * |
| AUTOIMMUNE | ||||||
| Teplizumab (Anti-CD3)(CD3) | T1D - Early Onset | * | * | * | * | * |
| T1D - At-Risk (NIH) | * | * | * | * | * | |
| OtherOther(CD32B x CD79B) | SLE, RA | * | * | * | * | * |
| OtherOther | Autoimmune | * | * | * | * | * |
| INFECTIOUS DISEASES | ||||||
| OtherOther | Emerging Diseases | * | * | * | * | * |
Overview
Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
Learn moreCompany Highlights
- Robust pipeline in oncology, autoimmunity and infectious diseases
- Partners include Boehringer Ingelheim, Gilead, Pfizer and Servier
- Fully-integrated biologics capabilities across product development process
- Strong financial position and blue-chip investor base
- Experienced management team and highly collaborative corporate culture
Partnering
.png)
Jan. '13 - Strategic alliance with Gilead on four DARTs.
Sep. '12 - Collaboration with Servier on multiple oncology DARTs.
Dec. '11 - Collaboration with Servier on MGA271.
Oct. '10 - Global DART partnerships with Pfizer and Boehringer Ingelheim. Learn more